SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
erickerickson
Olecranon
To: erickerickson who wrote (63297)11/24/2025 5:02:12 PM
From: sysiphus2 Recommendations  Read Replies (1) of 63312
 
Maybe:
  • In its Q3 2025 report, Monte Rosa announced a major new collaboration with Novartis, including a $120 million upfront payment and a potential total deal value up to $5.7 billion.

  • The company also disclosed that it has cash and marketable securities worth roughly $396.2 million (as of end-Sept 2025), giving the firm a cash runway that could fund operations through 2028.

  • Several drug candidates in its clinical pipeline (e.g. MRT-8102, MRT-6160, MRT-2359) are advancing toward key milestones over the next 6–12 months.

    • Report TOU ViolationShare This Post
     Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

    HomeMailHotSubjectMarksPeopleMarksKeepersSettings
    Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
    © 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News